GlassScriptPhysician profile
Minh V Bui
NPI 1447226824
$6,502.60
in general payments reported to CMS, 2019-2025
27 companies · $596 in 2025
The $596 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,275 · 2020: $624 · 2021: $1,034 · 2022: $940 · 2023: $624 · 2024: $410 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,629.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,596.72 | 2019-2025 | Aveir, Assurity, Gallant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.84 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $293.10 | 2019-2023 | |
| Medtronic, INC. | $287.61 | 2025 | Avalus, Penditure |
| Astrazeneca Pharmaceuticals LP | $255.79 | 2019-2023 | Farxiga |
| Merck Sharp & Dohme LLC | $231.92 | 2019-2023 | Verquvo |
| Amarin Pharma, INC. | $204.92 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $197.01 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $187.85 | 2019-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $166.30 | 2019-2023 | |
| Stryker Corporation | $127.28 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Chiesi USA, INC. | $123.25 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $99.75 | 2019-2023 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $64.59 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $42.22 | 2023 | Opsumit, Uptravi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $38.93 | 2022 | |
| Amgen INC. | $38.85 | 2019 | |
| Philips North America LLC | $33.43 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.20 | 2019 | |
| Glaxosmithkline, LLC. | $23.96 | 2019 | |
| Preventice Services, LLC | $22.94 | 2021 | |
| Xeris Pharmaceuticals, INC. | $22.28 | 2023 | Keveyis |
| Mylan Specialty L.P. | $22.03 | 2020 | |
| Boston Scientific Corporation | $21.61 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $21.45 | 2019 | |
| Edwards Lifesciences Corporation | $19.62 | 2019 | |
| Allergan, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minh Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.